NASDAQ · CLYM
Climb Bio, Inc.
$10.20-$0.13 (-1.21%)
Climb Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 44.33% below the high.
Loading market information…
NASDAQ · GTHX · USD
Stock price, earnings
Quote as of Sep 17, 2024, 07:56 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
G1 Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.42% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow G1 Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
G1 Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise focused on identifying, advancing, and ultimately commercializing small-molecule therapeutics to address various cancers. Their flagship commercial offering, COSELA, is designed to reduce chemotherapy-induced bone marrow suppression in adult patients with extensive-stage small cell lung cancer, administered prior to specific platinum/etoposide- or topotecan-containing regimens. The company is also actively progressing several investigational compounds. Trilaciclib, a CDK4/6 inhibitor, is currently undergoing extensive clinical evaluation, including Phase III studies for first-line colorectal cancer and first-line triple-negative breast cancer. Additionally, it is in Phase II trials for initial bladder cancer treatment, in combination with an antibody-drug conjugate, and as a neoadjuvant therapy for breast cancer. Their development pipeline further includes lerociclib, an oral CDK4/6 inhibitor intended for multiple oncological applications, and rintodestrant, an orally administered selective estrogen receptor degrader, which is in Phase IIa clinical trials for estrogen receptor-positive, HER2-negative breast cancer. G1 Therapeutics has forged several strategic licensing agreements. They have partnered with EQRx, Inc. and Genor Biopharma Co. Inc. for the oral formulation of lerociclib, encompassing all human indications. A separate collaboration with Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. covers the parenteral development and market introduction of trilaciclib for any human indication. Furthermore, the company works with ARC Therapeutics on a CDK2 inhibitor, designated for both human and veterinary uses. Established in 2008, G1 Therapeutics, Inc. is headquartered in Research Triangle Park, North Carolina.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:36 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2022 | Mar 1, 2023 | -$0.73+14.12% vs estimate | $10.25M+6.1% vs estimate |
|---|
| Q3 2022 | Nov 2, 2022 | -$0.59+7.81% vs estimate | $23.58M+1.06% vs estimate |
|---|
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.20-$0.13 (-1.21%)
Climb Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 44.33% below the high.
$10.15+$0.02 (+0.2%)
iTeos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.43% below the high.
$23.99-$0.01 (-0.04%)
Claritev Corporation’s quoted price sits in the lower half of its reported 52-week range, 67.44% below the high.
$2.10-$0.10 (-4.55%)
SomaLogic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.59% below the high.
$8.61+$0.02 (+0.23%)
Y-mAbs Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.55% below the high.
$3.65$0.00 (0.0%)
Revance Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.72% below the high.
$16.70+$0.05 (+0.3%)
Orchard Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
$8.05$0.00 (0.0%)
Vigil Neuroscience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.62% below the high.
